Interest in Savient Pharmaceuticals (SVNT) continues. Shares are up 50 cents to $6.25 and implied volatility remains elevated (250 percent), as investors brace for an FDA-appointed Athritis Advisory Committee review of Savient’s biologics license application scheduled for June 16. Today’s options trades reflect expectations for heightened volatility in SVNT shares as one player recently bought 2,500 June 2.5 put – June 10 call strangles while another bought 8,100 July 10 calls for 70 cents.